Appointment of Michael T. Heffernan as Member of the Board of Directors – In January 2020, Biohaven announced appointment of Michael T. Heffernan as a director to fill the vacancy created by the resignation of Robert Repella. Mr. Heffernan has also been appointed as a member and the chair of the Compensation Committee of the Board and a member of the Nominating and Governance Committee of the Board. Mr. Heffernan is a seasoned biopharmaceutical leader with over 25 years of commercial experience and most recently served as Founder and CEO of Collegium (Nasdaq: COLL ), and remains Chairman of its Board of Directors. Mr. Heffernan has been an advisor, investor and board member in a number of biopharmaceutical and healthcare services companies. His recent board memberships include: TyRx (sold to Medtronic), PreCision Dermatology (sold to Valeant), Ocata Therapeutics (sold to Astellas), and Veloxis (Sold to Asahi Kasei).